Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering

Gufeng Wang, Robert J. Lipert, Maneesh Jain, Sukwinder Kaur, Subhankar Chakraboty, Maria P. Torres, Surinder Kumar Batra, Randall E. Brand, Marc D. Porter

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Pancreatic cancer (PC) is one of the most lethal malignancies. It has a 5-year survival rate of only 6%, owing in part to the lack of a reliable tumor marker for early diagnosis. Recent research has shown that the mucin protein MUC4 is aberrantly expressed in pancreatic adenocarcinoma cell lines and tissues but is undetectable in normal pancreas and chronic pancreatitis. Thus, the level of MUC4 in patient sera has the potential to function as a diagnostic and prognostic marker for PC. However, the measurement of MUC4 in sera using conventional test platforms (e.g., enzyme linked immunosorbent assay (ELISA) and radioimmunoassay (RIA)) has been unsuccessful. This has prevented the assessment of the utility of this protein as a possible PC marker in sera. In addressing this obstacle, the work herein examines the potential to create a simple diagnostic test for MUC4 through the development of a surface-enhanced Raman scattering (SERS)-based immunoassay, which was then used to demonstrate the first ever detection of MUC4 in cancer patient serum samples. Importantly, these measurements showed that sera from patients with PC produced a significantly higher SERS response for MUC4 compared to sera from healthy individuals and from patients with benign diseases. These results indicate that a SERS-based immunoassay can monitor MUC4 levels in patient sera, representing a much needed first step toward assessing the potential of this protein to serve as a serum marker for the early stage diagnosis of PC. This paper details these and other findings (i.e., the detection of the mucin protein CA19-9), which demonstrate that our SERS assay outperforms conventional assays (i.e., RIA and ELISA) with respect to limits of detection, readout time, and required sample volume.

Original languageEnglish (US)
Pages (from-to)2554-2561
Number of pages8
JournalAnalytical chemistry
Volume83
Issue number7
DOIs
StatePublished - Apr 1 2011

Fingerprint

Raman scattering
Assays
Immunosorbents
Mucins
Proteins
Enzymes
Tumor Biomarkers
Cells
Tissue

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. / Wang, Gufeng; Lipert, Robert J.; Jain, Maneesh; Kaur, Sukwinder; Chakraboty, Subhankar; Torres, Maria P.; Batra, Surinder Kumar; Brand, Randall E.; Porter, Marc D.

In: Analytical chemistry, Vol. 83, No. 7, 01.04.2011, p. 2554-2561.

Research output: Contribution to journalArticle

Wang, Gufeng ; Lipert, Robert J. ; Jain, Maneesh ; Kaur, Sukwinder ; Chakraboty, Subhankar ; Torres, Maria P. ; Batra, Surinder Kumar ; Brand, Randall E. ; Porter, Marc D. / Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. In: Analytical chemistry. 2011 ; Vol. 83, No. 7. pp. 2554-2561.
@article{d2669dab6adb410daf3a992aafb982b2,
title = "Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering",
abstract = "Pancreatic cancer (PC) is one of the most lethal malignancies. It has a 5-year survival rate of only 6{\%}, owing in part to the lack of a reliable tumor marker for early diagnosis. Recent research has shown that the mucin protein MUC4 is aberrantly expressed in pancreatic adenocarcinoma cell lines and tissues but is undetectable in normal pancreas and chronic pancreatitis. Thus, the level of MUC4 in patient sera has the potential to function as a diagnostic and prognostic marker for PC. However, the measurement of MUC4 in sera using conventional test platforms (e.g., enzyme linked immunosorbent assay (ELISA) and radioimmunoassay (RIA)) has been unsuccessful. This has prevented the assessment of the utility of this protein as a possible PC marker in sera. In addressing this obstacle, the work herein examines the potential to create a simple diagnostic test for MUC4 through the development of a surface-enhanced Raman scattering (SERS)-based immunoassay, which was then used to demonstrate the first ever detection of MUC4 in cancer patient serum samples. Importantly, these measurements showed that sera from patients with PC produced a significantly higher SERS response for MUC4 compared to sera from healthy individuals and from patients with benign diseases. These results indicate that a SERS-based immunoassay can monitor MUC4 levels in patient sera, representing a much needed first step toward assessing the potential of this protein to serve as a serum marker for the early stage diagnosis of PC. This paper details these and other findings (i.e., the detection of the mucin protein CA19-9), which demonstrate that our SERS assay outperforms conventional assays (i.e., RIA and ELISA) with respect to limits of detection, readout time, and required sample volume.",
author = "Gufeng Wang and Lipert, {Robert J.} and Maneesh Jain and Sukwinder Kaur and Subhankar Chakraboty and Torres, {Maria P.} and Batra, {Surinder Kumar} and Brand, {Randall E.} and Porter, {Marc D.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1021/ac102829b",
language = "English (US)",
volume = "83",
pages = "2554--2561",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering

AU - Wang, Gufeng

AU - Lipert, Robert J.

AU - Jain, Maneesh

AU - Kaur, Sukwinder

AU - Chakraboty, Subhankar

AU - Torres, Maria P.

AU - Batra, Surinder Kumar

AU - Brand, Randall E.

AU - Porter, Marc D.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Pancreatic cancer (PC) is one of the most lethal malignancies. It has a 5-year survival rate of only 6%, owing in part to the lack of a reliable tumor marker for early diagnosis. Recent research has shown that the mucin protein MUC4 is aberrantly expressed in pancreatic adenocarcinoma cell lines and tissues but is undetectable in normal pancreas and chronic pancreatitis. Thus, the level of MUC4 in patient sera has the potential to function as a diagnostic and prognostic marker for PC. However, the measurement of MUC4 in sera using conventional test platforms (e.g., enzyme linked immunosorbent assay (ELISA) and radioimmunoassay (RIA)) has been unsuccessful. This has prevented the assessment of the utility of this protein as a possible PC marker in sera. In addressing this obstacle, the work herein examines the potential to create a simple diagnostic test for MUC4 through the development of a surface-enhanced Raman scattering (SERS)-based immunoassay, which was then used to demonstrate the first ever detection of MUC4 in cancer patient serum samples. Importantly, these measurements showed that sera from patients with PC produced a significantly higher SERS response for MUC4 compared to sera from healthy individuals and from patients with benign diseases. These results indicate that a SERS-based immunoassay can monitor MUC4 levels in patient sera, representing a much needed first step toward assessing the potential of this protein to serve as a serum marker for the early stage diagnosis of PC. This paper details these and other findings (i.e., the detection of the mucin protein CA19-9), which demonstrate that our SERS assay outperforms conventional assays (i.e., RIA and ELISA) with respect to limits of detection, readout time, and required sample volume.

AB - Pancreatic cancer (PC) is one of the most lethal malignancies. It has a 5-year survival rate of only 6%, owing in part to the lack of a reliable tumor marker for early diagnosis. Recent research has shown that the mucin protein MUC4 is aberrantly expressed in pancreatic adenocarcinoma cell lines and tissues but is undetectable in normal pancreas and chronic pancreatitis. Thus, the level of MUC4 in patient sera has the potential to function as a diagnostic and prognostic marker for PC. However, the measurement of MUC4 in sera using conventional test platforms (e.g., enzyme linked immunosorbent assay (ELISA) and radioimmunoassay (RIA)) has been unsuccessful. This has prevented the assessment of the utility of this protein as a possible PC marker in sera. In addressing this obstacle, the work herein examines the potential to create a simple diagnostic test for MUC4 through the development of a surface-enhanced Raman scattering (SERS)-based immunoassay, which was then used to demonstrate the first ever detection of MUC4 in cancer patient serum samples. Importantly, these measurements showed that sera from patients with PC produced a significantly higher SERS response for MUC4 compared to sera from healthy individuals and from patients with benign diseases. These results indicate that a SERS-based immunoassay can monitor MUC4 levels in patient sera, representing a much needed first step toward assessing the potential of this protein to serve as a serum marker for the early stage diagnosis of PC. This paper details these and other findings (i.e., the detection of the mucin protein CA19-9), which demonstrate that our SERS assay outperforms conventional assays (i.e., RIA and ELISA) with respect to limits of detection, readout time, and required sample volume.

UR - http://www.scopus.com/inward/record.url?scp=79953292019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953292019&partnerID=8YFLogxK

U2 - 10.1021/ac102829b

DO - 10.1021/ac102829b

M3 - Article

C2 - 21391573

AN - SCOPUS:79953292019

VL - 83

SP - 2554

EP - 2561

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 7

ER -